Sign In

Rick Hawkins

President & CEO at Lumos Pharma

Rick Hawkins is a distinguished professional with a remarkable track record in the pharmaceutical and biotechnology industries, receiving several prestigious awards and recognitions for his entrepreneurial excellence and leadership.

He is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame and the University of Texas College of Natural Sciences Hall of Honor, showcasing his exceptional contributions to the field.

Rick Hawkins holds a B.S. in Biology from Ohio University, providing him with a strong foundation in the life sciences that has guided his successful career.

Currently serving as the President and CEO of Lumos Pharma, Inc., he leads an early-stage orphan drug company based in Austin, Texas, demonstrating his commitment to advancing healthcare solutions.

In addition, Mr. Hawkins holds positions as a Board of Director for reputable companies like SciClone Pharmaceuticals Inc. and Cytori Therapeutics, Inc., where he continues to drive innovation and growth in the biopharmaceutical and stem cell research sectors.

With past leadership roles at id2 - Innovations in Drug Development and Savara Pharmaceuticals, as well as being the Former Chairman, President & Chief Executive Officer at Pharmaco, Rick Hawkins has a wealth of experience in executive management within the pharmaceutical industry.

His reputation as one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience Institute solidifies his standing as an influential figure in the life sciences landscape.

Throughout his career, Rick Hawkins has been recognized with prestigious awards such as the Distinguished Business Award from Ohio University and the Konneker Medal for entrepreneurial excellence, highlighting his significant contributions to the business and academic communities.

As a sought-after keynote speaker and industry expert, Rick Hawkins continues to inspire and drive advancements in biotechnology and pharmaceuticals, making a lasting impact on the industry.

Highlights

May 15 · Investing.com
Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 - Investing.com
Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 - Investing.com
Apr 18 · Yahoo Finance
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - Yahoo Finance
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - Yahoo Fina
Rick Hawkins
Add to my network

Location

Austin, Texas Area